Opportunity Information: Apply for RFA AI 21 006
The grant opportunity titled "Basic Research to Inform Vaccine and Therapeutic Development for Non-Polio Human Enteroviruses (NPEV) (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA AI 21 006) is a National Institutes of Health (NIH) discretionary funding program that supports basic research aimed at accelerating future medical countermeasures for non-polio enteroviruses. Its central goal is to expand foundational scientific understanding of NPEVs in ways that directly inform the development of two major types of interventions: (1) pan-enterovirus vaccines that could provide broad protection across multiple enterovirus types, and (2) broad-spectrum antiviral therapeutics that could work against a wide range of enteroviruses. The opportunity specifically emphasizes enteroviruses across species A, B, C, and D, reflecting the public health need created by the diversity of circulating non-polio enteroviruses and the challenge of creating solutions that remain effective despite viral variation.
This is an R01 mechanism, meaning it is designed for hypothesis-driven, investigator-initiated research projects that can support substantial, multi-year basic science efforts. The "Clinical Trial Not Allowed" designation is an important boundary for the scope of work: applicants are expected to propose non-clinical studies rather than human interventional trials. In practice, this points researchers toward laboratory, computational, and preclinical research activities such as studying viral biology, identifying conserved viral targets, understanding immune responses that can provide cross-protection, clarifying mechanisms of pathogenesis, and generating knowledge that can be translated into vaccine antigen design or antiviral drug target selection. The emphasis is on the kind of early-stage research that reduces key scientific unknowns and de-risks downstream product development, rather than funding late-stage testing in people.
Eligibility is broad and includes many types of domestic U.S. organizations as well as certain non-U.S. entities. Eligible applicants listed include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding institutions of higher education when specified); for-profit organizations other than small businesses; and small businesses. In addition, the announcement explicitly notes eligibility for a range of institution types and community-focused organizations, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and eligible federal government agencies. It also allows non-domestic (non-U.S.) entities (foreign organizations), which can be particularly relevant for enterovirus research given global circulation patterns and the value of international strain surveillance, specimen access, and specialized expertise.
The funding activity category is Health, and the CFDA number associated with the program is 93.855. The opportunity record indicates the original closing date was 2021-07-13, with a creation date of 2021-02-12. An award ceiling and expected number of awards are not specified in the provided source data, which typically means applicants would need to consult the full announcement or NIH budget guidance to understand practical budget expectations, limits (if any), and how awards might be sized relative to the proposed scope.
Overall, this announcement is aimed at strengthening the basic science pipeline for NPEV countermeasures by supporting research that identifies broadly conserved vulnerabilities across enteroviruses, clarifies immune correlates that could enable cross-type vaccine protection, and lays the groundwork for antivirals with activity against multiple enterovirus groups. The intended outcome is not a finished vaccine or drug from this award alone, but a stronger evidence base and clearer set of validated targets and principles that make pan-enterovirus vaccine and broad-spectrum antiviral development more feasible and faster to advance in later translational and clinical stages.Apply for RFA AI 21 006
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Basic Research to Inform Vaccine and Therapeutic Development for Non-Polio Human Enteroviruses (NPEV) (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2021-02-12.
- Applicants must submit their applications by 2021-07-13. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Basic Research to Inform Vaccine and Therapeutic Development for Non-Polio Human Enteroviruses (NPEV) (R01 Clinical Trial Not Allowed)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA AI 21 006.
Which agency is offering this funding?
This is a National Institutes of Health (NIH) discretionary funding opportunity.
What type of grant mechanism is this?
This funding uses the R01 mechanism, which supports hypothesis-driven, investigator-initiated research projects that can cover substantial, multi-year basic science efforts.
What is the main purpose of this funding opportunity?
The central goal is to support basic research that accelerates future medical countermeasures for non-polio human enteroviruses (NPEVs) by expanding foundational scientific understanding in ways that directly inform intervention development.
What kinds of interventions is this research meant to inform?
The opportunity is designed to inform two major intervention areas: (1) pan-enterovirus vaccines intended to provide broad protection across multiple enterovirus types, and (2) broad-spectrum antiviral therapeutics intended to work against a wide range of enteroviruses.
Which enteroviruses are emphasized by this announcement?
The opportunity specifically emphasizes enteroviruses across species A, B, C, and D.
Why is there an emphasis on broad protection or broad-spectrum activity?
The emphasis reflects the diversity of circulating non-polio enteroviruses and the challenge of developing solutions that remain effective despite viral variation. The research focus is on identifying broadly conserved vulnerabilities and immune responses that can support cross-protection.
Are clinical trials allowed under this opportunity?
No. The opportunity is designated "Clinical Trial Not Allowed," meaning applicants are expected to propose non-clinical studies rather than human interventional clinical trials.
What does "Clinical Trial Not Allowed" mean for the scope of proposed work?
It means proposed studies should remain non-clinical and focus on laboratory, computational, and preclinical research activities that generate knowledge to de-risk and inform downstream vaccine or antiviral development, rather than testing interventions in people.
What types of research activities fit the intent of this award?
Examples of activities consistent with the stated scope include studying viral biology, identifying conserved viral targets, understanding immune responses that can provide cross-protection, clarifying mechanisms of pathogenesis, and generating knowledge that can be translated into vaccine antigen design or antiviral drug target selection.
Is this funding intended to produce a finished vaccine or drug?
No. The intended outcome is not a finished vaccine or drug from this award alone, but a stronger evidence base and clearer set of validated targets and principles to make later translational and clinical development more feasible and faster to advance.
What is the funding activity category?
The funding activity category is Health.
What is the CFDA number associated with this program?
The CFDA number is 93.855.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. domestic organizations as well as certain non-U.S. entities (foreign organizations).
Are state, county, or local governments eligible?
Yes. Eligible applicants include state, county, and local governments, as well as special district governments.
Are educational institutions eligible to apply?
Yes. Eligible applicants include independent school districts, public and state-controlled institutions of higher education, and private institutions of higher education.
Are tribal governments or tribal organizations eligible?
Yes. Eligibility includes federally recognized Native American tribal governments and tribal organizations that are not federally recognized.
Are nonprofits eligible?
Yes. Eligible applicants include nonprofits with and without 501(c)(3) status (with the noted exclusion language in the source list regarding institutions of higher education when specified).
Are for-profit organizations eligible?
Yes. Eligible applicants include for-profit organizations other than small businesses, and small businesses.
Are public housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are listed as eligible applicants.
Are minority-serving institutions explicitly included?
Yes. The announcement explicitly notes eligibility for institution types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations allowed to apply?
Yes. The opportunity explicitly notes eligibility for faith-based or community-based organizations.
Are U.S. territories or possessions included in eligibility?
Yes. U.S. territories or possessions are explicitly included.
Are regional organizations eligible?
Yes. Regional organizations are explicitly listed as eligible.
Are federal government agencies eligible to apply?
Yes. Eligible federal government agencies are listed as eligible applicants.
Can non-U.S. (foreign) organizations apply?
Yes. The announcement allows non-domestic (non-U.S.) entities (foreign organizations).
Why might foreign organization eligibility be important for this topic area?
The topic area can benefit from international participation because non-polio enteroviruses circulate globally, and foreign organizations may contribute strain surveillance, specimen access, and specialized expertise.
What are the key scientific themes this opportunity aims to advance?
The announcement aims to strengthen the basic science pipeline for NPEV countermeasures by supporting work that identifies broadly conserved vulnerabilities across enteroviruses, clarifies immune correlates that could enable cross-type vaccine protection, and supports foundations for antivirals with activity against multiple enterovirus groups.
What is the original closing date shown for this opportunity?
The opportunity record indicates an original closing date of 2021-07-13.
What is the creation date shown for this opportunity?
The opportunity record indicates a creation date of 2021-02-12.
Is an award ceiling listed in the provided information?
No. An award ceiling is not specified in the provided source data.
Is the expected number of awards provided?
No. The expected number of awards is not specified in the provided source data.
What does it mean that award ceiling and number of awards are not specified?
Based on the provided information, it means those details are not included in the source record; applicants would typically need to consult the full announcement or NIH budget guidance to understand practical budget expectations, any limits (if applicable), and how awards may be sized relative to the proposed scope.
Browse more opportunities from the same category: Health
Next opportunity: Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
Previous opportunity: Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 21 006
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 21 006) also looked into and applied for these:
| Funding Opportunity |
|---|
| Tobacco Regulatory Science (R01 Clinical Trial Optional) Apply for RFA OD 21 002 Funding Number: RFA OD 21 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Frontier Health Markets APS Apply for 7200AA21APS00005 Funding Number: 7200AA21APS00005 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| Fogarty Global Trauma and Injury Research Training Program (D43 Clinical Trial Optional) Apply for RFA TW 21 003 Funding Number: RFA TW 21 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) Apply for PAR 21 120 Funding Number: PAR 21 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34 - Clinical Trial Not Allowed) Apply for PAR 21 146 Funding Number: PAR 21 146 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 21 007 Funding Number: RFA AI 21 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Facility and Building System Upgrades Support for the Regional Biocontainment Laboratories (G20 Clinical Trial Not Allowed) Apply for RFA AI 21 022 Funding Number: RFA AI 21 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Clinical Centers (Collaborative UG3/UH3 Clinical Trial Required) Apply for RFA HL 22 007 Funding Number: RFA HL 22 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maximizing Access to Research Careers (T34 - Clinical Trial Not Allowed) Apply for PAR 21 147 Funding Number: PAR 21 147 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mental Health Research Awards for Investigators Early in their Career in Low and Middle-Income Countries (R01 Clinical Trial Optional) Apply for RFA MH 21 120 Funding Number: RFA MH 21 120 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NINDS Institutional Research Training Program (T32 - Clinical Trial Not Allowed) Apply for PAR 21 149 Funding Number: PAR 21 149 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lung Transplant Consortium - Clinical Centers (U01 - Clinical Trial Not Allowed) Apply for RFA HL 22 002 Funding Number: RFA HL 22 002 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Lung Transplant Consortium - Data Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA HL 22 003 Funding Number: RFA HL 22 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The Midlife in the United States Study (U19 Clinical Trial Not Allowed) Apply for PAR 21 156 Funding Number: PAR 21 156 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed) Apply for PAR 21 157 Funding Number: PAR 21 157 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Triadic Interactions in Clinical Encounters Involving People with Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional) Apply for RFA AG 22 020 Funding Number: RFA AG 22 020 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required) Apply for PAR 21 133 Funding Number: PAR 21 133 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) Apply for PAR 21 135 Funding Number: PAR 21 135 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) Apply for PAR 21 134 Funding Number: PAR 21 134 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) Apply for PAR 21 131 Funding Number: PAR 21 131 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 21 006", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.